Document is current

Article History

Received: 24 September 2024

Accepted: 27 December 2024

First Online: 1 February 2025

Declarations

:

: J. García-Corbacho reports travel expenses from BMS and Pfizer and honoraria from Astra Zeneca, GSK, Lilly, Regeneron, Roche and Pfizer. L. Mezquita reports grants/research support from Amgen, Inivata, AstraZeneca and Gilead, honoraria/consultation fees from Roche, Takeda, Janssen and MSD, lectures and educational activities for Bristol-Meyers Squibb, Roche, Takeda, AstraZeneca, MSD, Radonova and Janssen, travel accommodation/expenses from Bristol-Meyers Squibb, Roche, Takeda, AstraZeneca and Janssen. F. Brasó-Maristany reports patent application (PCT/EP2022/086493, PCT/EP2023/060810, EP23382703 and EP23383369). N. Basté participated in advisory boards for Nanobiotix, Merck Serono, MSD, BioNtech, Roche, and BMS. T. Saurí served as a consultant at AstraZeneca, BMS, Roche, MSD, AMGEN, and Daiichi Sankyo and received lecture fees from BMS and MSD; B. Mellado reports research funding from Janssen, Roche, Bayer, and Pfizer; speakers’ bureau for Roche, Sanofi, Janssen, Astellas, Pfizer, Novartis, and Bristol-Myers Squibb; and travel and accommodation expenses from Janssen and Pfizer. Ò. Reig reports consulting or advisory role for BMS, EISAI, and Ipsen; and travel and accommodation expenses from Ipsen and Pfizer. L. Gaba reports advisory and consulting fees from GlaxoSmithKline, AstraZeneca, Merk Sharp Dohme, and PharmaMar, honoraria from GlaxoSmithKline, AstraZeneca, Merk Sharp Dohme, and PharmaMar for educational events/materials and travel expenses from GlaxoSmithKline, AstraZeneca, Merk Sharp Dohme. A. Prat reports advisory and consulting fees from AstraZeneca, Roche, Pfizer, Novartis, Daiichi Sankyo, and Peptomyc, lecture fees from AstraZeneca, Roche, Novartis, and Daiichi Sankyo, institutional financial interests from AstraZeneca, Novartis, Roche, and Daiichi Sankyo; stockholder and employee of Reveal Genomics; patents filed PCT/EP2016/080056, PCT/EP2022/086493, PCT/EP2023/060810, EP23382703 and EP23383369. F. Schettini reports honoraria from Novartis, Gilead, Veracyte and Daiichy-Sankyo for educational events/materials, advisory fees from Pfizer and Veracyte, and travel expenses from Novartis, Gilead and Daiichy-Sankyo. The other authors report no conflict of interest.

: The study protocol was approved by the Ethic Committee of the HCB (IRB n. HCB/2017/0371) and was conducted according to the Declaration of Helsinki, good clinical practice guidelines and in compliance with applicable national and local laws. All patients signed an informed consent before entering the study.